Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trial
Official title:
A Naturalistic Prospective Study of Treatment Effectiveness for ADHD
To determine if there is a clinically and statistically significant difference between OROS-MPH and IR MPH in ADHA and ODD symptoms by the parent completed SNAP-IV. It is hypothesized that OROS-MPH is superior in improving symptom outcomes overall, remission rate, functional improvement, quality of life and persistence with medication over time.
This one-year prospective observational study is designed to evaluate and compare outcomes
effectiveness between OROS-MPH and IR MPH in ADHA and ODD symptoms at the ADHD Clinic of the
British Columbia Children's and Women's Health Centre. A practical clinical trial is
valuable because it has the potential to provide us the information which represents the
actual outcomes in real settings.
The primary objective of this study is to analyze the treatment outcomes of ADHD patients
under conditions of routine clinical practice. Patients will, therefore, be treated
according to the current practice of each participating physician, with the exception of
several additional rating scales which are SNAP-IV, Strengths and Difficulties
Questionnaire, WEISS Functional Impairment Rating Scale (WFIRS)-Parent, Child Health and
Illness Profile (CHIP), EQ-5D, Parent/Caregiver Questionnaire, ADHD Side Effect Checklist,
Adolescent Diversion Questionnaire, Adaptive Behavior Assessment System-Second Edition
(ABAS-2) and Clinic Global Impressions. Patients will be assessed at baseline and 12 months
regardless of whether the original treatment is continued. If a patient terminates the study
early, all assessments that are normally collected at the end of the study will be collected
at the time of termination. Only patients with pre and post data will be included in the
analysis.
Results of this study are expected to make breakthrough on the treatment of ADHD in
practice; and, particularly, information which come out from this study is not currently
available from other researches.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02150668 -
Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD
|
N/A | |
Completed |
NCT00631280 -
Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD
|
N/A | |
Recruiting |
NCT05809388 -
Virtual Reality for Parent Training Intervention
|
N/A | |
Completed |
NCT00776009 -
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
|
Phase 4 | |
Recruiting |
NCT00252278 -
Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
|
Phase 4 | |
Completed |
NCT04016779 -
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
|
Phase 3 | |
Completed |
NCT00307268 -
Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD
|
N/A | |
Completed |
NCT01107496 -
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
|
Phase 1/Phase 2 | |
Completed |
NCT04786990 -
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
|
Phase 4 | |
Completed |
NCT00711724 -
Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD
|
N/A | |
Completed |
NCT00475735 -
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
|
Phase 2 | |
Recruiting |
NCT06215144 -
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
|
Phase 2/Phase 3 | |
Completed |
NCT02633527 -
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
|
Phase 2 | |
Not yet recruiting |
NCT04532190 -
Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder
|
N/A | |
Withdrawn |
NCT00931398 -
Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate
|
Phase 4 |